| Code | CSB-RA011664MB4HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to EBI-031, specifically targeting interleukin-6 (IL-6), a pleiotropic cytokine that plays a central role in immune regulation and inflammatory responses. IL-6 is produced by various cell types including T cells, macrophages, and fibroblasts, and signals through both classical and trans-signaling pathways to influence acute phase responses, hematopoiesis, and immune cell differentiation. Dysregulated IL-6 production is implicated in numerous pathological conditions including rheumatoid arthritis, inflammatory bowel disease, cytokine release syndrome, and various malignancies where it promotes tumor progression and therapeutic resistance.
EBI-031 is a humanized monoclonal antibody that selectively inhibits IL-6 signaling and has been investigated in clinical studies for ocular inflammatory conditions and other IL-6-mediated disorders. This biosimilar provides researchers with a valuable tool for investigating IL-6 biology, exploring inflammatory disease mechanisms, evaluating therapeutic intervention strategies, and studying cytokine signaling networks in various experimental models. The antibody enables detailed examination of IL-6's role in both physiological and pathological processes.
There are currently no reviews for this product.